Molecular Therapy: Methods & Clinical Development (Dec 2020)
Rapid Lentiviral Vector Producer Cell Line Generation Using a Single DNA Construct
- Yu Hua Chen,
- Celeste Pallant,
- Christopher J. Sampson,
- Alessia Boiti,
- Sabine Johnson,
- Pijus Brazauskas,
- Philip Hardwicke,
- Michela Marongiu,
- Vanesa M. Marinova,
- Marlene Carmo,
- Nathan P. Sweeney,
- Ashkenaz Richard,
- Anthony Shillings,
- Peter Archibald,
- Eva Puschmann,
- Bernadette Mouzon,
- David Grose,
- Miriam Mendez-Tavio,
- Mao Xiang Chen,
- Stephen R.C. Warr,
- Tarik Senussi,
- Paul S. Carter,
- Sean Baker,
- Cindy Jung,
- Martijn H. Brugman,
- Steven J. Howe,
- Conrad A. Vink
Affiliations
- Yu Hua Chen
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Celeste Pallant
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Christopher J. Sampson
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Alessia Boiti
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Sabine Johnson
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Pijus Brazauskas
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Philip Hardwicke
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Michela Marongiu
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Vanesa M. Marinova
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Marlene Carmo
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Nathan P. Sweeney
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Ashkenaz Richard
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Anthony Shillings
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Peter Archibald
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Eva Puschmann
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Bernadette Mouzon
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- David Grose
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Miriam Mendez-Tavio
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Mao Xiang Chen
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Stephen R.C. Warr
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Tarik Senussi
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Paul S. Carter
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Sean Baker
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Cindy Jung
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Martijn H. Brugman
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Steven J. Howe
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK
- Conrad A. Vink
- GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK; Corresponding author: Conrad A. Vink, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK.
- Journal volume & issue
-
Vol. 19
pp. 47 – 57
Abstract
Stable suspension producer cell lines for the production of vesicular stomatitis virus envelope glycoprotein (VSVg)-pseudotyped lentiviral vectors represent an attractive alternative to current widely used production methods based on transient transfection of adherent 293T cells with multiple plasmids. We report here a method to rapidly generate such producer cell lines from 293T cells by stable transfection of a single DNA construct encoding all lentiviral vector components. The resulting suspension cell lines yield titers as high as can be achieved with transient transfection, can be readily scaled up in single-use stirred-tank bioreactors, and are genetically and functionally stable in extended cell culture. By removing the requirement for efficient transient transfection during upstream processing of lentiviral vectors and switching to an inherently scalable suspension cell culture format, we believe that this approach will result in significantly higher batch yields than are possible with current manufacturing processes and enable better patient access to medicines based on lentiviral vectors.